Alzamend Neuro, Inc.
ALZN
$2.22
-$0.14-5.93%
NASDAQ
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 959.30K | 688.80K | 590.30K | 1.05M | 755.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.70M | 1.14M | 1.04M | 1.36M | 962.40K |
| Operating Income | -2.70M | -1.14M | -1.04M | -1.36M | -962.40K |
| Income Before Tax | -2.70M | -1.14M | -1.04M | -1.36M | -974.40K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.70M | -1.14M | -1.04M | -1.36M | -974.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.70M | -1.14M | -1.04M | -1.36M | -974.40K |
| EBIT | -2.70M | -1.14M | -1.04M | -1.36M | -962.40K |
| EBITDA | -2.67M | -1.13M | -1.02M | -1.35M | -949.70K |
| EPS Basic | -1.28 | -2.43 | -1.70 | -3.61 | -11.42 |
| Normalized Basic EPS | -0.80 | -1.00 | -1.06 | -2.17 | -7.14 |
| EPS Diluted | -1.28 | -2.43 | -1.70 | -3.61 | -11.42 |
| Normalized Diluted EPS | -0.80 | -1.00 | -1.06 | -2.17 | -7.14 |
| Average Basic Shares Outstanding | 2.11M | 711.30K | 613.10K | 392.40K | 85.30K |
| Average Diluted Shares Outstanding | 2.11M | 711.30K | 613.10K | 392.40K | 85.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |